4,567 Shares in Palomar Holdings, Inc. $PLMR Purchased by Summit Global Investments

Summit Global Investments purchased a new stake in shares of Palomar Holdings, Inc. (NASDAQ:PLMR) during the third quarter, HoldingsChannel.com reports. The firm purchased 4,567 shares of the company’s stock, valued at approximately $533,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Invesco Ltd. increased its stake in shares of Palomar by 234.1% during the second quarter. Invesco Ltd. now owns 798,361 shares of the company’s stock valued at $123,147,000 after buying an additional 559,383 shares during the period. Alliancebernstein L.P. lifted its stake in Palomar by 290.2% in the second quarter. Alliancebernstein L.P. now owns 497,080 shares of the company’s stock worth $76,675,000 after acquiring an additional 369,697 shares during the period. AustralianSuper Pty Ltd bought a new stake in Palomar in the second quarter valued at $37,253,000. Orion Porfolio Solutions LLC boosted its holdings in Palomar by 2,753.2% in the second quarter. Orion Porfolio Solutions LLC now owns 180,491 shares of the company’s stock valued at $27,841,000 after acquiring an additional 174,165 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in Palomar by 65.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 196,624 shares of the company’s stock valued at $30,324,000 after purchasing an additional 77,992 shares during the period. Hedge funds and other institutional investors own 90.25% of the company’s stock.

Insider Transactions at Palomar

In other Palomar news, CFO T Christopher Uchida sold 2,103 shares of Palomar stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $119.88, for a total transaction of $252,107.64. Following the completion of the transaction, the chief financial officer owned 11,473 shares in the company, valued at approximately $1,375,383.24. The trade was a 15.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Knutzen sold 1,535 shares of the firm’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $119.88, for a total value of $184,015.80. Following the transaction, the insider owned 24,809 shares of the company’s stock, valued at $2,974,102.92. The trade was a 5.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 34,146 shares of company stock worth $4,224,679. Company insiders own 3.70% of the company’s stock.

Key Stories Impacting Palomar

Here are the key news stories impacting Palomar this week:

• Neutral Sentiment: Yahoo Finance published a piece asking whether PLMR’s recent price slide creates a long‑term buying opportunity — a constructive framing for value investors but speculative. Is Palomar Holdings (PLMR) Price Slide Creating A Long Term Opportunity For Investors
• Negative Sentiment: CEO Mac Armstrong sold 11,484 shares at $119.88 (≈$1.38M); his post-sale holding is 91,737 shares (11.13% decrease). SEC filing: CEO Sale Filing
• Negative Sentiment: President Jon Christianson sold 1,991 shares at $119.88 (≈$238.7k); post-sale holding 62,985 shares (3.06% decrease). SEC filing: President Sale Filing
• Negative Sentiment: CFO T. Christopher Uchida sold 2,103 shares at $119.88 (≈$252.1k); post-sale holding 11,473 shares (15.49% decrease). SEC filing: CFO Sale Filing
• Negative Sentiment: Insider Jonathan Knutzen sold 1,535 shares at $119.88 (≈$184.0k); post-sale holding 24,809 shares (5.83% decrease). SEC filing: Insider Sale Filing
• Negative Sentiment: Insider Angela L. Grant sold 1,447 shares at $119.88 (≈$173.5k); post-sale holding 5,242 shares (21.63% decrease). SEC filing: Insider Sale Filing

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, January 14th. Keefe, Bruyette & Woods increased their price target on shares of Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. raised their price objective on shares of Palomar from $145.00 to $155.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen upgraded Palomar from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $159.50.

Palomar Price Performance

Shares of Palomar stock opened at $123.59 on Friday. The company has a 50-day moving average of $127.65 and a 200 day moving average of $123.83. The firm has a market cap of $3.28 billion, a price-to-earnings ratio of 19.28 and a beta of 0.42. Palomar Holdings, Inc. has a 1 year low of $104.47 and a 1 year high of $175.85.

Palomar (NASDAQ:PLMR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.56 by $0.45. The business had revenue of $244.66 million for the quarter, compared to analyst estimates of $207.98 million. Palomar had a net margin of 22.59% and a return on equity of 21.93%. During the same quarter in the previous year, the firm posted $1.23 earnings per share. On average, equities analysts anticipate that Palomar Holdings, Inc. will post 5.99 EPS for the current year.

Palomar Company Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.